BioSpace13m
BMS’ Schizophrenia Approval, Pfizer’s Sudden Sickle Cell Withdrawal and Roche’s Pharma Day
Bristol Myers Squibb wins approval for the first novel schizophrenia drug in decades; Pfizer pulls Oxbryta from the market; ...
Short E-mini S&P 500: Break below key support, bearish divergence confirms downside
2nd October Long MKC: McCormick Extends Uptrend After Strong Q3 Earnings, Targeting Short-Term Gains 2nd October Long ES: ...
Long MKC: McCormick Extends Uptrend After Strong Q3 Earnings, Targeting Short-Term Gains
After 12 years working for big fashion brands as a Project Manager and Data Analyst,... read more.
Bristol-Myers tops growth chart among S&P 500 healthcare stocks in Q3
The Health Care Select Sector SPDR Fund ETF (NYSEARCA:XLV), tracking the healthcare companies under S&P 500, rose 6.27% in ...
Pharmaceutical Technology36m
Exscientia outline robot and AI use in drug discovery workflow
Exscientia detailed how its robotics lab in Oxfordshire, UK is increasing productivity and efficiency in developing new ...